Ballester Javier, Valentine Gerald, Sofuoglu Mehmet
a Department of Psychiatry , Yale School of Medicine , New Haven , CT , USA.
b VA Connecticut Healthcare System , West Haven , CT , USA.
Expert Rev Clin Pharmacol. 2017 Mar;10(3):305-314. doi: 10.1080/17512433.2017.1268916. Epub 2016 Dec 20.
Methamphetamine (MA) abuse remains a global health challenge despite intense research interest in the development of pharmacological treatments. This review provides a summary of clinical trials and human studies on the pharmacotherapy of methamphetamine use disorder (MUD). Areas covered: We summarize published clinical trials that tested candidate medications for MUD and also conducted PubMed and Google Scholar searches to identify recently completed clinical trials using the keywords 'methamphetamine' 'addiction' 'pharmacotherapy' and 'clinical trial.' To determine the status of ongoing clinical trials targeting MUD, we also searched the ClinicalTrials.gov online database. We conclude this review with a discussion of current research gaps and future directions. Expert commentary: Clinical trials examining the potential for pharmacotherapies of MUD have largely been negative. Future studies need to address several limitations to reduce the possibility of Type II errors: small sample sizes, high dropout rates or multiple comorbidities. Additionally, new treatment targets, such as MA-induced disruptions in cognition and in the neuroimmune system, merit trials with agents that selectively modulate these processes.
尽管对药物治疗的开发有着浓厚的研究兴趣，但甲基苯丙胺（MA）滥用仍然是一项全球性的健康挑战。本综述总结了关于甲基苯丙胺使用障碍（MUD）药物治疗的临床试验和人体研究。涵盖领域：我们总结了已发表的测试MUD候选药物的临床试验，并在PubMed和谷歌学术上进行搜索，以使用关键词“甲基苯丙胺”“成瘾”“药物治疗”和“临床试验”来识别最近完成的临床试验。为了确定针对MUD的正在进行的临床试验的状态，我们还搜索了ClinicalTrials.gov在线数据库。我们在本综述结尾讨论了当前的研究差距和未来方向。专家评论：检验MUD药物治疗潜力的临床试验大多结果为阴性。未来的研究需要解决几个局限性，以降低II型错误的可能性：样本量小、高辍学率或多种合并症。此外，新的治疗靶点，如MA引起的认知和神经免疫系统破坏，值得用选择性调节这些过程的药物进行试验。
